PRESS-RELEASE ·Filed Mar 17, 2026
Press release: fda
Actionable Insight • Neutral
Monitor the AACR presentations for data on Zymeworks' preclinical or early clinical candidates, which could influence sentiment if results are compelling. No immediate catalyst for valuation change.
Final — all horizons settled through T+60d
ZYME ▼ -2.07% at T+60d
NEUTRAL call ✗ call lost -2.07% · α vs SPY -13.59% · entry $23.45 → $22.97
T+1d
+1.90%
call +1.90% · α +2.16%
$23.90
settled 7mo ago
T+5d
+3.33%
call +3.33% · α +4.04%
$24.23
settled 6mo ago
T+20d
+15.99%
call +15.99% · α +9.94%
$27.20
settled 6mo ago
T+60d
-2.07%
call -2.07% · α -13.59%
$22.97
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
Zymeworks announced the acceptance of an oral presentation and six abstracts from its R&D portfolio for presentation at the 2026 AACR Annual Meeting. This highlights ongoing research activity but does not represent a material clinical or regulatory milestone.
Key Facts
- Zymeworks will present one oral presentation and six posters at the AACR Annual Meeting 2026.
- Presentations are from the company's wholly-owned R&D portfolio.
- Event takes place April 17–22, 2026, in San Diego, CA.
Financial Impact
No direct financial impact disclosed
Risk Factors
- Presented data may be preliminary or preclinical, with limited near-term commercial relevance.
- Lack of detailed results in the press release limits near-term trading catalyst potential.
Market Snapshot
Exchange
Nasdaq
Investment Themes
Biotech & Drug Discovery
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257732 |
12 reports for ZYME
88% Hit rate best @ T+60▲ +16.72%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | 8-K | $27.47 $27.50 | ▲ +0.11% | ▼ −0.87% | $25.15 (−8.45%) |
Jul 16, 2026 11w ago | Press Release | $24.19 $25.76 | ▼ −6.49% | ▼ −2.87% | $25.15 (−3.97%) |
Jun 29, 2026 13w ago | Press Release | $24.10 $22.86 | ▼ −5.15% | ▼ −4.87% | $25.15 (+4.36%) |
Jun 14, 2026 15w ago | Press Release | $23.26 $24.94 | ▲ +7.22% | ▲ +7.97% | $25.15 (+8.13%) |
May 15, 2026 19w ago | 3 | $24.43 $22.49 | ▼ −7.94% | ▼ −9.52% | $25.15 (+2.95%) |
Apr 21, 2026 23w ago | Press Release | $28.53 $24.40 | ▼ −14.48% | ▼ −17.64% | $25.15 (−11.85%) |
Apr 17, 2026 24w ago | Press Release | $27.80 $23.96 | ▼ −13.81% | ▼ −19.18% | $25.15 (−9.53%) |
Apr 16, 2026 24w ago | Press Release | $27.20 $24.57 | ▼ −9.67% | ▼ −15.48% | $25.15 (−7.54%) |
Apr 10, 2026 25w ago | 3 | $26.17 $24.03 | ▼ −8.18% | ▼ −15.91% | $25.15 (−3.90%) |
Mar 17, 2026 28w ago | Press Release | $23.45 $27.20 | ▲ +15.99% | ▲ +9.94% | $25.15 (+7.25%) |
Showing 10 of 12
US Market Status
Market Closed — Opens Mon (65h 9m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access